Biểu đồ giá cổ phiếu RNTX
RNTX Giá
Rein Therapeutics Inc
$1.17
14.7%
$0.14
Khi đóng cửa: May 06, 16:00:00 GMT-4
$1.13
-3.41%
$-0.04
Phiên trước giờ: May 07, 09:08:07 GMT-4
Quay lại
Rein Therapeutics Inc (RNTX) Giá
Thống kê chính
Giá đóng cửa trước
$1.02
Giá mở cửa
$1.04
Phạm vi ngày
$1.02 - $1.2
Phạm vi 52 tuần
$1 - $2.4
Khối lượng
3.5M
Khối lượng trung bình
274.9K
Tỷ suất cổ tức
--
EPS (TTM)
-1.84
Vốn hóa thị trường
$31.6M
RNTX là gì?
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
